Table 2 Adverse events associated with different neoadjuvant therapy in patients with renal cell carcinoma
Adverse event | Axitinib [cases (%)] | Sunitinib [cases (%)] | Sorafenib [cases (%)] | P 1 | P 2 | P 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
All grade | Grade 1–2 | Grade 3–4 | All grade | Grade 1–2 | Grade 3–4 | All grade | Grade 1–2 | Grade 3–4 | ||||
Hand–foot syndrome | 6 (40.0) | 5 (33.3) | 1 (6.7) | 13 (54.2) | 10 (41.7) | 3 (12.5) | 16 (53.3) | 13 (43.3) | 3 (10.0) | 0.389 | 0.399 | 0.951 |
Hypertension | 6 (40.0) | 5 (33.3) | 1 (6.7) | 11 (45.9) | 8 (33.3) | 3 (12.5) | 13 (43.3) | 10 (33.3) | 2 (6.7) | 0.721 | 0.831 | 0.854 |
Diarrhea | 4 (29.4) | 4 (29.4) | 0 (0.0) | 9 (37.5) | 9 (37.5) | 0 (0.0) | 12 (40.0) | 11 (36.7) | 1 (3.3) | 0.485 | 0.378 | 0.852 |
Nausea | 4 (26.7) | 4 (26.7) | 0 (0.0) | 8 (33.3) | 8 (33.3) | 0 (0.0) | 8 (26.7) | 8 (26.7) | 0 (0.0) | 0.092 | 1.000 | 0.594 |
Fatigue | 4 (26.7) | 4 (26.7) | 0 (0.0) | 7 (29.1) | 7 (29.1) | 0 (0.0) | 8 (26.7) | 8 (26.7) | 0 (0.0) | 0.150 | 1.000 | 0.839 |
Loss of appetite | 3 (20.0) | 3 (20.0) | 0 (0.0) | 6 (25.0) | 6 (25.0) | 0 (0.0) | 7 (23.3) | 7 (23.3) | 0 (0.0) | 0.718 | 0.800 | 0.887 |
Leukocytopenia | 2 (13.3) | 2 (13.3) | 0 (0.0) | 11 (45.9) | 8 (33.3) | 3 (12.5) | 8 (26.7) | 7 (23.3) | 1 (3.3) | 0.036 | 0.526 | 0.143 |
Thrombocytopenia | 2 (13.3) | 2 (13.3) | 0 (0.0) | 12 (50.0) | 9 (37.5) | 3 (12.5) | 7 (23.3) | 7 (23.3) | 0 (0.0) | 0.020 | 0.693 | 0.041 |
lymphocytopenia | 2 (13.3) | 3 (13.3) | 0 (0.0) | 8 (33.3) | 5 (20.8) | 3 (12.5) | 4 (13.3) | 4 (13.3) | 0 (0.0) | 0.310 | 1.000 | 0.079 |
Anemia | 2 (13.3) | 2 (13.3) | 0 (0.0) | 5 (20.8) | 4 (15.8) | 1 (4.2) | 7 (23.3) | 6 (20.0) | 1 (3.3) | 0.638 | 0.890 | 0.826 |
Hypothyroidism | 2 (13.3) | 2 (13.3) | 0 (0.0) | 6 (25.0) | 8 (25.0) | 0 (0.0) | 4 (13.33) | 4 (13.33) | 0 (0.0) | 0.638 | 1.000 | 0.457 |